MARKET

CBAY

CBAY

Cymabay Therapeu
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.945
-0.025
-1.27%
Opening 09:55 05/27 EDT
OPEN
1.980
PREV CLOSE
1.970
HIGH
1.980
LOW
1.925
VOLUME
26.39K
TURNOVER
33.79K
52 WEEK HIGH
5.06
52 WEEK LOW
1.670
MARKET CAP
164.70M
P/E (TTM)
-1.4679
1D
5D
1M
3M
1Y
5Y
CymaBay's New Seladelpar Two-Year Data Shows Improved Transplant-Free Survival
Benzinga · 4d ago
CymaBay announces result from two-year study of primary biliary cholangitis therapy
CymaBay Therapeutics (NASDAQ:CBAY -4.3%) said on Monday that results from a new analyses of clinical studies showed that seladelpar treatment through two years resulted in a decrease in Primary Biliary Cholangitis globe
Seekingalpha · 4d ago
CymaBay Therapeutics Says Seladelpar Reduces Need for Liver Transplants
MT Newswires · 4d ago
CymaBay Therapeutics Presents New Findings That Seladelpar Treatment Of PBC Patients For Two Years Predicts Improved Transplant-Free Survival
CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced that results
Benzinga · 4d ago
CymaBay Therapeutics Presents New Findings that Seladelpar Treatment of PBC Patients for Two Years Predicts Improved Transplant-Free Survival
NEWARK, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced t...
GlobeNewswire · 4d ago
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Benzinga · 05/18 12:17
B. Riley Lowers Cymabay Therapeutics' Price Target to $8 from $10 to Account for Slightly Delayed Launch Timeline, Higher Cost of Capital; Keeps Buy Rating
MT Newswires · 05/18 10:23
CymaBay price target lowered at H.C. Wainwright on enrollment delay for key study
H.C. Wainwright has trimmed the price target on the clinical-stage biopharma company CymaBay Therapeutics (NASDAQ:CBAY) on Monday, citing a delay in the enrollment for the second global Phase 3 trial
Seekingalpha · 05/16 19:58
More
No Data
Learn about the latest financial forecast of CBAY. Analyze the recent business situations of Cymabay Therapeu through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

37.50%Strong Buy
62.50%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CBAY stock price target is 9.89 with a high estimate of 14.00 and a low estimate of 7.00.
High14.00
Average9.89
Low7.00
Current 2.030
EPS
Actual
Estimate
-0.27-0.20-0.14-0.07
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 192
Institutional Holdings: 78.27M
% Owned: 92.44%
Shares Outstanding: 84.68M
TypeInstitutionsShares
Increased
37
3.01M
New
21
640.88K
Decreased
24
790.32K
Sold Out
16
1.47M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.72%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Non-Executive Chairman/Independent Director
Robert Wills
President/Chief Executive Officer/Director
Sujal Shah
Senior Vice President/Chief Scientific Officer
Charles McWherter
Chief Compliance Officer/General Counsel/Secretary
Paul Quinlan
Vice President - Finance
Daniel Menold
Other
Klara Dickinson
Other
Dennis Kim
Other
Lewis Stuart
Director
Janet Dorling
Director
Eric Lefebvre
Independent Director
Caroline Loewy
Independent Director
Kurt von Emster
Independent Director
Thomas Wiggans
No Data
No Data
About CBAY
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company is focused on developing and providing access to therapies for patients with liver and other chronic diseases. Its pipeline includes three clinical stage product candidates, such as seladelpar, MBX-2982 and CB-0406. It also has one preclinical stage product candidate, CB-001. The Company's lead product candidate, seladelpar, is a potent and selective agonist of peroxisome proliferator activated receptor delta (PPARd), a nuclear receptor that regulates genes directly or indirectly involved in the synthesis of bile acids/sterols, metabolism of lipids and glucose, inflammation and fibrosis. Its MBX-2982 targets G protein-coupled receptor 119 (GPR119), a receptor that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion. Its CB-001 targets G protein-coupled receptor 120 (GPR120), a receptor for omega-3 fatty acids, such as docosahexaenoic acid (DHA).

Webull offers kinds of CymaBay Therapeutics Inc stock information, including NASDAQ:CBAY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CBAY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CBAY stock methods without spending real money on the virtual paper trading platform.